O-GlcNAcylation—a new diagnostic tool for type 2 diabetes mellitus?

Leukocyte O-GlcNAcylation: A novel diagnostic tool for the earlier detection of type 2 diabetes mellitus?

Vildagliptin: a new oral treatment for type 2 diabetes mellitus

Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell responsiveness to glucose. An extensive clinical program involving approximately 22,000 patients and 7000 patient-years of exposure to vildagliptin has shown that the agent is well tolerated and efficacious in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). Monotherapy trials have show...

Phlorotannins: Towards New Pharmacological Interventions for Diabetes Mellitus Type 2.

Diabetes mellitus is a group of metabolic disorders characterized by hyperglycaemia, and predicted by the World Health Organization as the expected 7th leading cause of death in 2030. Diabetes mellitus type 2 (DMT2) comprises the majority of diabetic individuals around the world (90%-95%). Pathophysiologically, this disorder results from a deregulation of glucose homeostasis, worsened by overwe...

New treatments for patients with type 2 diabetes mellitus.

In subjects with type 2 diabetes, both defects of insulin secretion and insulin resistance contribute to the development of hyperglycaemia. The major goals of treatment are to optimise blood glucose control, and normalise the associated lipid disturbances and elevated blood pressure. Pharmacologic treatment is often necessary. This paper discusses new forms of oral treatment for subjects with t...

Prevalence of Onychomycosis in Type 2 Diabetes Mellitus

Abstract Background and Objective: Onychomycosis is a fungal nail infection causing ulcers, diabetic foot and enhance nail infection. This study was designed to evaluate the prevalence of onychomycosis in type II diabetes. Material and methods: This descriptive-analytic study was conducted on 300 diabetic patients selected randomly among those referred to Panje Azar endocrinology clinic. ...